Business Wire

AlertEnterprise Looks to Transform Physical Security with Reveal of New Security AI Chatbot Powered by ChatGPT

28.2.2023 17:00:00 EET | Business Wire | Press release

Share

AlertEnterprise, Inc., the leading cyber-physical security convergence software company, today revealed the launch of its first-ever Guardian AI Chatbot powered by OpenAI ChatGPT. The company will debut the AI Chatbot globally end of March at the ASIS Europe and ISC West trade events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005630/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine. The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting. (Graphic: Business Wire)

The Guardian AI Chatbot is developed with the world-renowned GPT-3 platform created by OpenAI and is designed to instantly deliver security operators the physical access and security insights that matter most with quick questions and prompts.

“Physical security and access control systems have always contained a tremendous wealth of data but, until now, accessing it was a tedious and manual process,” said Yogesh Ailawadi, SVP Product and Solutions Engineering at AlertEnterprise. “Our Guardian AI Chatbot is poised to redefine the security operator’s experience, increasing their productivity by over 100 times with instant and actionable insights for not only risk mitigation but real business value.”

Mr. Ailawadi noted that the Guardian AI Chatbot is part of the launch of AlertEnterprise’s next-gen AI technology and is completely integrated throughout the Guardian platform.

Get powerful answers in an instant

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine.

The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting.

Some examples are:

  • “Guardian, how many people are on the Trading floor?”
  • “Guardian, how many employees and visitors are in the Data Center?”
  • “Guardian, how many new employee badges did we issue last month?”
  • “Guardian, show me upcoming employee training expirations for restricted area access.”

Drive costs down. Boost employee efficiency.

Using Guardian and its AI Chatbot, CSO and CISO’s can exponentially boost their team’s efficiency by automating tedious tasks and freeing up time to focus on more critical responsibilities. Guardian also leverages a company’s current security investments by connecting to most leading access control vendors and over 200 out-of-the-box connectors to HR, IT and OT systems. And if the organization has a complex mix of access control systems, Guardian connects to and consolidates them all under one platform.

AlertEnterprise founder and CEO Jasvir Gill says there’s no better time for CSO and CISO’s to invest in hyper-efficiency boosting AI platforms like Guardian. “Despite economic headwinds, the world’s most forward-looking CSO and CISO’s are accelerating security digital transformation. With Guardian’s deep forensics and AI data-driven insights, CSO and CISO’s can transform their access control from the stone age to the digital age—making every part of their SOC more automated, expeditious and cost effective, and ultimately the organization more secure. That’s why I view the AlertEnterprise Guardian platform as a deflationary fighting force for companies today.”

To see a live demonstration of the Guardian AI Chatbot, visit AlertEnterprise at Stand C5 at ASIS Europe in Rotterdam, NL, and Booth #13115 at ISC West in Las Vegas, USA.

AlertEnterprise

At AlertEnterprise, cyber-physical identity and trust are at the center of everything we do. Our mission is to bring people, processes, data and technology together in a unique way to help organizations protect what matters most. We call it security convergence. And we develop game-changing security convergence solutions that deliver identity governance, access management, security intelligence and compliance validation across enterprise IT, HR, cyber and physical security environments.

AlertEnterprise is committed to using AI in a responsible and ethical manner. We recognize the importance of protecting customer data and safeguarding against potential misuse of AI technology. As such, we have implemented strict policies and procedures to ensure the ethical use of AI and to protect the privacy and security of our customers' data. We believe that transparency and accountability are critical in this regard and remain dedicated to upholding these values throughout our development and operations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Willem Ryan – Senior Vice President of Marketing and Communications
Email: media@alertenterprise.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye